Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan

Wiener Medizinische Wochenschrift

Volumn 155, Issue 15-16, 2005, Pages 376-380

  Halank, Michael ^a   Kolditz, Martin ^a   Miehlke, Stephan ^a   Schiemanck, Steffen ^a   Schmeisser, Alexander ^b   Hoeffken, Gert ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b University Heart Center Dresden   (Germany)

Author keywords

Bosentan; Iloprost; Liver cirrhosis; Portopulmonary hypertension; Pulmonary hypertension

Indexed keywords

BOSENTAN; ILOPROST;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ECHOCARDIOGRAPHY; HUMAN; INTENSIVE CARE UNIT; MALE; PULMONARY HYPERTENSION; ULTRASOUND;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; ILOPROST; INJECTIONS, INTRAVENOUS; LIVER CIRRHOSIS, ALCOHOLIC; MALE; RECURRENCE; SULFONAMIDES; TIME FACTORS;

EID: 24744458364     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-005-0196-y     Document Type: Article

References (30)

1. McDonnel PJ, Toye PA, Hutchins GM (1983) Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 127: 437-441
2. Cheng EY, Woehlck HJ (1992) Pulmonary artery hypertension complicating anesthesia for liver transplantation. Anesthesiology 77: 389-392
3. Castro M, Krowka MJ, Schroeder R, Beck KC, Plevak DJ, Rettke SR, et al (1996) Frequency and clinical implications of increased pulmonary pressures in liver transplant patients. Mayo Clin Proc 71: 543-551
4. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F (2003) Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52: 1355-1362
5. Hoeper MM, Krowka MJ, Strassburg CP (2004) Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 363: 1461-1468
6. Robalino BD, Moodie DS (1991) Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 17: 492-498
7. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P (1998) Pulmonary vascular disorders in portal hypertension. Eur Respir J 11: 1153-1166
8. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH (1999) Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30: 641-648
9. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ (1997) Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63: 604-606
10. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, et al (1998) Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 65: 457-459
11. Molnar C, Alber H, Colleslli D, Vogel W, Kähler CM (2004) Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr 116: 627-630
12. Minder S, Fischler M, Muellhaupt B, Zalunadro MP, Jenni R, Clavien PA, Speich R (2004) Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 24: 703-707
13. Halank M, Miehlke S, Höffken G, Schmeisser A, Schulze M, Strasser RH (2004) Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 77: 1775-1776
14. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W (2004) Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2: 1039-1042
15. Kähler CM, Graziadei I, Wiedermann CJ, Kneussl MP, Vogel W (2000) Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 112: 637-640
16. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth, HJ, Schauer J, et al (2005) Bosentan therapy for portopulmonary hypertension. Eur Resp J 25: 502-508
17. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 197: 216-223
18. Rich S World Symposium on Primary Pulmonary Hypertension 1998: Executive Summary. http://www.who.int/ncd/cvd/pph.html
19. Swanson KS, Krowka MJ, Wiesner RH, McGoon MD (2003) Long-term survival in portopulmonary hypertension. Am J Respir Crit Care Med 167: A683
20. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S (1998) Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79: 175-179
21. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, Ewert R (2003) Assessment of the vasodilator response in primary pulmonary hypertension. Eur Heart J 24: 356-365
22. McLaughlin VV, Genthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with longterm epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277
23. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780-788
24. McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482
25. Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H (2002) Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 20: 339-343
26. Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, et al (2005) Clinical efficacy and survival with first line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J (in press)
27. Rubin LJ, Badesch DB, Barst R, Galie N, Black CM, Keogh A, et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903
28. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J (2004) Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 24: 1007-1010
29. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al (2003) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158-164
30. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24: 353-359